PBM Pharmaceuticals, Inc. (Buchanan Ingersoll & Rooney PC) - Supplement
|
This Other document was issued by the Food and Drug Administration (FDA)
For related information,
Open Docket Folder
Content
See attached file(s)
No documents available.
Attachments( 44 )PBM Pharmaceuticals Inc Buchanan Ingersoll amd Rooney PC Supplement Includes Attachment A
View Attachment:
PBM Pharmaceuticals Inc Buchanan Ingersoll amd Rooney PC Supplement Attachment BAttachment 1 Berman et al The GI Cocktail is no More Effective Than Plain Liquid Antacid A Randomized Double Blind Clinical TrialAttachment 2 Camilleri et al Brain Gut Axis From Basic Understanding to Treatment of IBS and Related DisordersAttachment 3 Chey et al Pharmacologic and Complementary and Atternative Medicine Therapies for Irritable Bowel Syndrome
View Attachment:
Attachment 4 Ciccaglione et al Effect of Hydoscine N Butylbromide on Gastroesophageal Reflux in Normal Subjects and Patients With...Attachment 5 Clouse Therapy Update Antidepressants for Irritable Bowel SyndromeAttachment 6 Crowell et al New Insights Into the Pathophysiology of Irritable Bowel Syndrome Implications for Future TreatmentsAttachment 7 Dotevall et al Controlled Clinical Trial of Mepiprazole in Irritable Bowel SyndromeAttachment 8 Fang et al Cholinergic Blockage Inhibits Gastro Oesophageal Reflux and Transient Lower Oesophageal Sphincter...Attachment 10 Ge et al Efficacy and Tolerability of Two Oral Hyoscine Butylbromide Formulations in Chinese Patients With Recurrent...Attachment 11 Guglielmetti et al Randomised Clinical Trial Bifidobacterium Bifidum MiMBb75 Significantly Alleviates Irritable...Attachment 12 Hardoin et al Colic Medication and Apparent Life Threatening EventsAttachment 13 Katiraei et al Need for a Comprehensive Medical Approach to the Neuroimmuno Gastroenterology of Irritable Bowel...Attachment 14 Khalif et al Interactions Between Symptoms and Motor and Visceral Sensory Responses of Irritable Bowel Syndrome...Attachment 15 Klooker et al The Mast Cell Stabiliser Ketotifen Decreases Visceral Hypersensitivity and Improves Intestinal...Attachment 16 Konturek et al Stress and the Gut Pathophysiology Clinical Consequences Diagnostic Approach and Treatment OptionsAttachment 17 Leventer et al Clinical Trial Dextofisopam in the Treatment of Patients With Diarrhoea Predominant or Alternating...Attachment 18 Lichstein et al Drug Therapy of the Unstable Bowel Irritable Colon A 15 Month Double Blind Clnical Study in 75 Cases...Attachment 19 Lidums et al Effect of Atropine on Gastrooesophageal Reflux and Transient Lower Oesophageal Sphincter Relaxations in...Attachment 20 Lydiard et al Irritable Bowel Syndrome Anxiety and Depression What Are the LinksAttachment 21 Mach The Brain Gut Axis in Irritable Bowel Syndrome Clinical AspectsAttachment 22 Marks Clinical and XRay Evaluation of Donnatal and Donnatal Extentabs in Functional Disturbances of the...Attachment 24 Mueller Lissner et al Placebo and Paracetamol Controlled Study on the Efficacy and Tolerability of Hyoscine...Attachment 25 Myers et al Role of Anxiety in the Pathophysiology of Irritable Bowel Syndrome Importance of the AmygdalaAttachment 26 North et al Relationship of Functional Gastrointestinal Disorders and Psychiatric Disorders Implications for...Attachment 27 OMalley et al Do Interactions Between Stress and Immune Responses Lead to Symptom Exacerbations in Irritable Bowel...Attachment 28 Pinto et al Stressful Life Events Anxiety Depression and Coping in Patients of Irritable Bowel SyndromeAttachment 29 Rhodes et al Controlled Clinical Trial of Sedative Anticholinergic Drugs in Patients with the Irritable Bowel...Attachment 30 Ritchie et al Comparison of Various Treatments for Irritable Bowel SyndromeAttachment 31 Stutts et al Cholestatic Jaundice With Skin Desquamation in a 12 Year Old GirlAttachment 32 Tack et al A Controlled Crossover Study of the Selective Serotonin Reuptake Inhibitor Citalopram in Irritable Bowel...Attachment 33 Tack et al A Randomised Controlled Trial Assessing the Efficacy and Safety of Repeated Tegaserod Therapy in Women...Attachment 34 Winfield Treatment of Nonspecific Afebrile Diarrheas With DonnagelAttachment 35 Wittmann et al Clinical Trial The Efficacy of Alverine Citrate Simeticone Combination on Abdominal Pain Discomfort...Attachment 37 Zakko et al Randomised Clinical Trial the Clinical Effects of a Novel Neurokinin Receptor Antagonist DNK333 in Women...Attachment 38 Randomized Placebo Controlled Efficacy and Safety Study Investigating GW876008 in Patients With Irritable Bowel...
View Attachment:
Attachment 39 Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome
View Attachment:
Attachment 40 Eight Weeks of Treatment With Talnetant in Subjects With Irritable Bowel Syndrome IBS
View Attachment:
Attachment 41 Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
View Attachment:
|
|
Comment Period Closed
ID:
FDA-1975-N-0337-0002
Tracking Number:
Submitter Information
Country:
United States
State or Province:
DC
Submitter's Representative:
Buchanan Ingersoll & Rooney PC
Category:
Private Industry - C0003
Comments
0
Comments Received
*
Docket Information
This document is contained in
Related Dockets:
None
Related RINs:
None
*
The total reflects comments received from Regulations.gov and other means as of 11:59 PM yesterday. All comments received may not be posted at this time including bulk submissions; therefore, the total comments received and posted may differ.
|
